These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 23873427)

  • 1. Changes of plasma fibroblast growth factor-21 (FGF-21) in oral glucose tolerance test and effects of metformin on FGF-21 levels in type 2 diabetes mellitus.
    Zhang M; Liu Y; Xiong ZY; Deng ZY; Song HL; An ZM
    Endokrynol Pol; 2013; 64(3):220-4. PubMed ID: 23873427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Metformin on Fibroblast Growth Factor-21 Levels in Patients with Newly Diagnosed Type 2 Diabetes.
    Fan H; Sun X; Zhang H; Liu J; Zhang P; Xu Y; Pan Q; Wang G
    Diabetes Technol Ther; 2016 Mar; 18(3):120-6. PubMed ID: 26950284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus.
    Li K; Li L; Yang M; Zong H; Liu H; Yang G
    Eur J Endocrinol; 2009 Sep; 161(3):391-5. PubMed ID: 19528204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term effects of metformin in type 2 diabetes.
    Eriksson A; Attvall S; Bonnier M; Eriksson JW; Rosander B; Karlsson FA
    Diabetes Obes Metab; 2007 Jul; 9(4):483-9. PubMed ID: 17587390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitiglinide treatment may decreases plasma fibroblast growth factor-21 levels in individuals with new-onset T2DM.
    Wang B; Yang G; Yang M; Liao Y; Li Z; Boden G; Li L
    Cytokine; 2012 Feb; 57(2):300-3. PubMed ID: 22129626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of short-term continuous subcutaneous insulin infusion on fasting plasma fibroblast growth factor-21 levels in patients with newly diagnosed type 2 diabetes mellitus.
    Yang M; Dong J; Liu H; Li L; Yang G
    PLoS One; 2011; 6(10):e26359. PubMed ID: 22046277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of short-term metformin treatment on insulin sensitivity of blood glucose and free fatty acids.
    Iannello S; Camuto M; Cavaleri A; Milazzo P; Pisano MG; Bellomia D; Belfiore F
    Diabetes Obes Metab; 2004 Jan; 6(1):8-15. PubMed ID: 14686957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione.
    Kautzky-Willer A; Tura A; Winzer C; Wagner OF; Ludvik B; Hanusch-Enserer U; Prager R; Pacini G
    Diabetes Obes Metab; 2006 Sep; 8(5):561-7. PubMed ID: 16918591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retinol-binding protein 4 (RBP-4) levels do not change after oral glucose tolerance test and after dexamethasone, but correlate with some indices of insulin resistance in humans.
    Lewandowski KC; Basinska-Lewandowska M; Bieńkiewicz M; Randeva HS; Lewiński A
    Endokrynol Pol; 2008; 59(4):305-11. PubMed ID: 18777500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
    Sharma PK; Bhansali A; Sialy R; Malhotra S; Pandhi P
    Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term effects of metformin in type 2 diabetes.
    Eriksson A; Attvall S; Bonnier M; Eriksson JW; Rosander B; Karlsson FA
    Diabetes Obes Metab; 2007 May; 9(3):330-6. PubMed ID: 17391159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin.
    Chazova I; Almazov VA; Shlyakhto E
    Diabetes Obes Metab; 2006 Jul; 8(4):456-65. PubMed ID: 16776753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.
    DeFronzo RA; Barzilai N; Simonson DC
    J Clin Endocrinol Metab; 1991 Dec; 73(6):1294-301. PubMed ID: 1955512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes.
    Eguchi K; Tomizawa H; Ishikawa J; Hoshide S; Numao T; Fukuda T; Shimada K; Kario K
    Hypertens Res; 2007 Jan; 30(1):23-30. PubMed ID: 17460368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visfatin levels do not change after the oral glucose tolerance test and after a dexamethasone-induced increase in insulin resistance in humans.
    Marcinkowska M; Lewandowski KC; Lewiński A; Bieńkiewicz M; Basińska-Lewandowska M; Salata I; Randeva HS
    Endokrynol Pol; 2007; 58(3):188-94. PubMed ID: 17940983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fıbroblast growth factor 21 and ıts relatıonshıp wıth ınsulın sensıtıvıty ın fırst-degree relatıves of patıents wıth type 2 dıabetes mellıtus.
    Ors D; Eroglu Altinova A; Yalçın MM; Gulbahar O; Akturk M; Arslan M; Balos Toruner F
    Endokrynol Pol; 2016; 67(3):260-4. PubMed ID: 26884286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of PEGylated FGF-21 with insulin glargine for long-lasting hypoglycaemic effect in db/db mice.
    Ye X; Qi J; Wu Y; Yu D; Xu P; Li S; Zhu S; Wu Q; Ren G; Li D
    Diabetes Metab; 2015 Feb; 41(1):82-90. PubMed ID: 25451186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-diabetic effects of compound K versus metformin versus compound K-metformin combination therapy in diabetic db/db mice.
    Yoon SH; Han EJ; Sung JH; Chung SH
    Biol Pharm Bull; 2007 Nov; 30(11):2196-200. PubMed ID: 17978500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.